RBC Capital Issues Negative Sentiment on Sage Therapeutics (SAGE), 'we are not altogether surprised by the stock move'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $26.00 price target on Sage Therapeutics (NASDAQ: SAGE).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
